From CBC News:
New legislation in Ontario designed to curb the price of prescription drugs through bulk discounts will scare away investors by creating a "transactional relationship" between government and drug developers, the head of GlaxoSmithKline Inc.'s (NYSE:GSK) Canadian operations said Tuesday.
The Transparent Drug System for Patients Act will have a ripple effect across the country by encouraging the use of copy-cat medication and cutting into drug company revenues, Paul Lucas said in a speech to pharmaceutical investors in Toronto. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment